EXPOSÉ
LS_015[2017]

Active ingredients for the treatment of lung in Idiopathic Pulmonary Fibrosis - IPF



Correction of maladaptive ER-re-sponse, blockade of epithelial apoptosis primary target molecules
(patent application / life science / procedure)

Active ingredients for the treatment of lung in Idiopathic Pulmonary Fibrosis - IPF

Abstract:
The new substances for the treatment of patients with sporadic idiopathic pulmonary fibrosis (IPF) are intended to effect the correct lysosomal processing of the surfactant protein B and / or the blockade of an epithelial maladaptative ER-stress response.

[pdf-Dokument]

Inventor(s):
Prof. Dr. Andreas Günther, Dr. Martina Korfei , Prof. Dr. Philipp Markart, Dr. Clemens Ruppert , Prof. Dr. Werner Seeger



Contact:
TransMIT GmbH
Michaela Kirndörfer
Kerkrader Str. 3
D-35394 Giessen
Phone: +49-(0)641-94364-16
Fax: +49-(0)641-94364-99
michaela.kirndoerfer@transmit.de